MP-0250 is under clinical development by Molecular Partners and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect MP-0250’s likelihood of approval (LoA) and phase transition for Refractory Multiple Myeloma took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MP-0250 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

MP-0250 overview

MP-0250 is under development for the treatment of relapsed and refractory multiple myeloma (Kahler disease). It is administered as intravenous infusion. The therapeutic candidate is a bi-specific protein targeting both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF). It is based on DARPin platform. It was also under development for the treatment of colorectal cancer, liver cancer, pancreatic cancer, gastric cancer, renal cancer, non-small cell lung cancer, cervical cancer, head and neck cancer, advanced malignancy, nasopharyngeal cancer and lung cancer.

Molecular Partners overview

Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration. It also develops drugs on DARPin base technology and other product candidates. Molecular Partners develops products for ophthalmic conditions, cancer, immune disorders and other indications. The company also provides clinical trial services and small protein therapies called Darpin therapeutics. It has partnership with a pharmaceutical company to strengthen drug platforms through in-house development, licensing and collaboration. Molecular Partners is headquartered in Zurich, Switzerland.

Quick View MP-0250 LOA Data

Report Segments
  • Innovator
Drug Name
  • MP-0250
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.